Tafamidis
Tafamidis is a pharmaceutical drug with 21 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
11
Early Stage
0
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
21 of 21 finished
0.0%
0 ended early
0
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
Clinical Trials (21)
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics
Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)
A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers
A Study Comparing Amounts of Tafamidis In The Blood Without Food
A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food
A Bioequivalence Study Comparing Two Different Tafamidis Formulations
A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21